Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval-Reference-Cited by-同舟云学术

Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval

Published:2023-04-01 Issue:4 Volume:9 Page:567
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Parikh Ravi B.¹,Hubbard Rebecca A.¹,Wang Erkuan¹,Royce Trevor J.²,Cohen Aaron B.²,Clark Amy S.¹,Mamtani Ronac¹

Affiliation:

1. Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania

2. Flatiron Health, New York, New York

Abstract

This cross-sectional study evaluates patient exposure to oncology drugs withdrawn from the US Food and Drug Administration (FDA) Accelerated Approval program.

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2801800/jamaoncology_parikh_2023_ld_220036_1681755688.66868.pdf

Reference6 articles.

1. A 25-year experience of US Food and Drug Administration accelerated approval of malignant hematology and oncology drugs and biologics: a review.;Beaver;JAMA Oncol,2018

2. Analysis of FDA’s accelerated approval program performance December 1992-December 2021.;Beakes-Read;Ther Innov Regul Sci,2022

3. The on- and off-ramps of oncology accelerated approval.;Fashoyin-Aje;N Engl J Med,2022

4. Center for Drug Evaluation and Research. Ongoing: cancer accelerated approvals. U.S. Food and Drug Administration. Published August 16, 2022. Accessed October 1, 2022. https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals?

5. Center for Drug Evaluation and Research. Withdrawn: cancer accelerated approvals. U.S. Food and Drug Administration. Published June 1, 2022. Accessed October 1, 2022. https://www.fda.gov/drugs/resources-information-approved-drugs/withdrawn-cancer-accelerated-approvals?

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Financial Toxicity of Withdrawn Poly (Adenosine Diphosphate Ribose) Polymerase Inhibitor Indications for Ovarian Cancer;Value in Health;2024-09

2. A landscape of methodology and implementation of adaptive designs in cancer clinical trials;Critical Reviews in Oncology/Hematology;2024-08

3. Continued cancer drug approvals in Japan and Europe after market withdrawal in the United States: A comparative study of accelerated approvals;Clinical and Translational Science;2024-07

4. A Systematic Review of Adaptive Seamless Clinical Trials for Late-Phase Oncology Development;Therapeutic Innovation & Regulatory Science;2024-06-11

5. Current regulatory status in China of drugs withdrawn from the US FDA accelerated pathway: implications for regulation globally;The Lancet Oncology;2024-06